RAPT Therapeutics, Inc. (RAPT) EBITDA (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed EBITDA for 5 consecutive years, with -$53.3 million as the latest value for Q4 2024.
- Quarterly EBITDA fell 73.91% to -$53.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$129.9 million through Dec 2024, down 11.36% year-over-year, with the annual reading at -$129.9 million for FY2024, 11.36% down from the prior year.
- EBITDA hit -$53.3 million in Q4 2024 for RAPT Therapeutics, down from -$18.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$12.2 million in Q2 2020 to a low of -$53.3 million in Q4 2024.
- Historically, EBITDA has averaged -$22.6 million across 5 years, with a median of -$19.9 million in 2022.
- Biggest YoY gain for EBITDA was 41.63% in 2024; the steepest drop was 73.91% in 2024.
- Year by year, EBITDA stood at -$13.0 million in 2020, then plummeted by 40.0% to -$18.2 million in 2021, then decreased by 23.89% to -$22.5 million in 2022, then tumbled by 36.09% to -$30.7 million in 2023, then tumbled by 73.91% to -$53.3 million in 2024.
- Business Quant data shows EBITDA for RAPT at -$53.3 million in Q4 2024, -$18.3 million in Q3 2024, and -$27.7 million in Q2 2024.